p53 Review Article

You have free access to this content

TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance†

  1. Shoshana Peller1,*,
  2. Varda Rotter2

Article first published online: 24 FEB 2003

DOI: 10.1002/humu.10190

Issue

Human Mutation

Human Mutation

Special Issue: Focus on p53 and Cancer

Volume 21, Issue 3, pages 277–284, March 2003

Additional Information

How to Cite

Peller, S. and Rotter, V. (2003), TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance. Hum. Mutat., 21: 277–284. doi: 10.1002/humu.10190

Author Information

  1. 1

    Laboratory of Hematology, Assaf-Harofeh Medical Center, Zerifin Israel

  2. 2

    Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, Israel

*Laboratory of Hematology, Assaf-Harofeh Medical Center, Zerifin, 70300, Israel

  1. †

    For the p53 Special Issue

Publication History

  1. Issue published online: 24 FEB 2003
  2. Article first published online: 24 FEB 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (127K)

REFERENCES

  • Barnabas N, Shurafa M, Van Dyke DL, Wolman SR, Clark D, Wersham MJ. 2001. Significance of p53 mutations in patients with chronic lymphocytic leukemia. Cancer 91:285–293.
    Direct Link:
  • Beck Z, Kiss A, Toth FD, Szabo J, Bacsi A, Balogh E, Borbely A, Telek B, Kovacs E, Olah E, Rak K. 2000. Alterations of p53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia. Leuk Lymphoma 38:587–597.
  • Bénard J, Douc-Rasy S, Ahomadegbe J-C. 2003. The TP53 family members and human cancers. Hum Mutat 21:192–200.
    Direct Link:
  • Callet-Bauchu E, Salles G, Gazzo S, Poncet C, Morel D, Pages J, Coeur P, Felman P. 1999. Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome. Leukemia 13:460–468.
  • Campo E, Reffeld M, Jaffe ES. 1999. Mantle-cell lymphoma. Sem Hematol 36:115–127.
  • Capello D, Gaidano G. 2000. Molecular pathophysiology of indolent lymphoma. Hematologica 85:195–201.
  • Capoulade C, Mir LM, Carlier K, Lecluse Y, Tetaud C, Mishal Z, Wiels J. 2001. Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides. Blood 97:1043–1049.
  • Christiansen DH, Andersen MK, Pedersen-Bjergaard J. 2001. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss or 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 19:1405–1413.
  • Cobo F, Martinez A, Pinyol M, Hernandez L, Gomez M, Bea S, Esteve J, Rozman M, Bosch F, Lopea-Guillermo A, Montserrat E, Campo E. 2002. Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia. Leukemia 16:1028–1034.
  • Cogliatti SB, Griesser H, Peng H, Du MQ, Lsaacson PG, Zimmermann DR, Maibach RC, Schmid U. 2000. Significantly different BCL-2 expression profiles in gastric and non-gastric primary extravodal high-grade B-Cell lymphomas. J Pathol 192:470–478.
    Direct Link:
  • Colley SM, Chappell DS, Busfield SJ, Voon DC, Klinken SP. 2000. Karyotypic abnormalities associated with haemopoietic lineage switching are not linked with mutations to p53. Int J Biochem Cell Biol 32:509–517.
  • Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, Venga ML, Gugliemi C, Mancini F, Giuliacci S, Sacchi A, Mandelli F, Foa R. 1998. P53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 91:4342–4349.
  • Cotter FE. 1999. Antisense therapy of hematologic malignancies. Sem Hematol 36:9–14.
  • De Angeli C, Gandini D, Cuneo A, Moretti S, Bigoni R, Roberti MG, Bardi A, Castoldi GL, Del Senno L. 2000. BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;p32). Haematologica 85:913–921.
  • Drexler HG. 1998. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12:845–859.
  • Drexler HG, Fombonne S, Matsuo Y, Hu ZB, Hamaguchi H, Uphoff CC. 2000. P53 alterations in human leukemia-lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization? Leukemia 14:198–206.
  • El-Deiry W, Harper J, Pretenpol J, Burrell M, Hill D, Wang Y, Wiman K, Mercer W, Kastan M, Kohn K, Elledge S, Kinzler K, Vogelstein B. 1994. WAFI/CIPI is induced in p53 mediated G(1) arrest and apoptosis. Cancer Res 54:1169–1174.
  • El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, De H, Bazarbachi A. 2000. Arsenic-interferon-α-triggered apoptosis in HTLV-I transformed cells is associated with Tax down-regulation and reversal of NF-kB activation. Blood 96:2849–2855.
  • Gronbaek K, Nekergaard T, Andersen MK, Thor Straten P, Guldberg P, Moller P, Zeuthen J, Ebbe Hansen N, Hou Jensen K, Ralfkiaer E. 1998. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, P15, P53 and pRb. Leukemia 12:1266–1271.
  • Gronbaek K, de Nully Brown P, Moller MB, Nedergaard T, Ralfkiaer E, Moller P, Zeuthen J, Guldberg P. 2000. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 14:1727–1735.
  • Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D. 2001. P53 abnormalities in splenic lymphoma with villous lymphocytes. Blood 97:3552–3558.
  • Harris CC. 1996. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442–1455.
  • Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296–299.
  • Hercher C, Robain M, Davi F, Garand R, Flandrin G, Valensi F, Vandeputte H, Albert A, Maynadie M, Troussard X, Simon GH, Lespinasse J, Portefaix G, Merle-Beral H. 2001. A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma 42:981–987.
  • Herr I, Debatin KM. 2001. Cellular stress response and apoptosis in cancer therapy. Blood 98:2603–2614.
  • Hirose M, Kuroda Y. 1998. P53 may mediate the mdr-1 expression via the WT1 gene in human vincristine resistant leukemia lymphoma cell lines. Cancer 129:165–171.
  • Ichikawa A, Kinoshita T, Watanabe TM, Kato H, Nagai H, Tsushita K, Saito H, Hotta T. 1997. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529–534.
  • Kawamura M, Ohnishi H, Guo SX, Sheng XM, Minegishi M, Hanada R, Horibe K, Hongo T, Kaneko Y, Bessho F, Yanagisawa M, Sekiya T, Hayashi Y. 1999. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leukemia 23:115–126.
  • Kirsch DG, Kastan MB. 1998. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 16:3158–3168.
  • Konig EA, Kusser WC, Day C, Porzsolt F, Glickman BW, Messer G, Schmid M, de-Chatel R, Marcsek ZL, Demeter J. 2000. P53 mutations in hairy cell leukemia. Leukemia 14:706–711.
  • Krug U, Ganser A, Koeffler HP. 2002. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21:3475–3495.
  • Lane D. 1992. P53 guardian of the genome. Nature 358:15–16.
  • Lazaridou A, Miraxtsi C, Korantzis J, Eleftheriadis N, Christakis JI. 2000. Simultaneous detection of BCL-2 protein, trisonomy 12, retinoblastoma and p53 monoallelic gene. Leuk Lymphoma 36:503–512.
  • Levine A. 1997. p53 the cellular gatekeeper for growth and division. Cell 88:323–331.
  • Martin A, Flaman J-M, Frebourg T, Davi F, El-ManSouri S, Amouroux J, Raphael M. 1998. Functional analysis of the p53 protein in AIDS-related non-Hodgkin's lymphomas and polymorphic lymphoprosiferations. Br J Haemat 101:311–317.
    Direct Link:
  • Masdehors P, Merle-Beral H, Maloum K, Omura S, Magdelenat H, Delic J. 2000. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-cell lymphocytes. Blood 96:269–274.
  • Megonigal MD, Rappaport FE, Nowell PC, Lange BJ, Felix CA. 1998. Potential role for wild-type p53 in leukemias with MLL gene translocations. Oncogene 16:1351–1356.
  • Moller MB, Ino Y, Gerdes A-M, Skjodt K, Louis DN, Pedersen NT. 1999. Aberrations of the p53 pathway components p53, MDM2, and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia 13:453–459.
  • Nakano Y, Naoe T, Kiyoi H, Kitamura K, Minami S, Miyawaki S, Asou N, Kuriyama K, Kusumoto S, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Saito H, Ohno R. 2000. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. Eur J Haematol 65:23–31.
    Direct Link:
  • Padua RA, Guinn B-A, Al-Sabah A, Smith M, Taylor C, Pettersson T, Ridge S, Carter G, White D, Oscier D, Chevret S, West R. 1998. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 12:887–892.
  • Pallis M, Grundy M, Turzanski J, Kofler R, Russell N. 2001. Mitochondrial membrane sensitivity to depolarization in acute myelobastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status. Blood 98:405–413.
  • Palucka KA, Knaust E, Xu D, Macnamara B, Porwit-Macdonald A, Gruber A, Peterson C, Bjorkholm M, Pisa P. 1999. Intraclonal heterogeneity in the in vitro daunorubicin-induced apoptosis in acute myeloid leukemia. Leuk Lymphoma 32:309–316.
  • Pan Y, Haines DS. 1999. The pathway regulating MDM2 protein degradation can be altered in human leukemic cells. Cancer Res 59:2064–2067.
  • Panayiotidis P, Kotsi P. 1999. Genetics of Small Lymphocyte Disorders. Sem Hematol 36:171–177.
  • Peller S. 1998. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. Cancer Biol 8:379–387.
  • Peller S, Yona R, Kopilova Y, Prokocimer M, Goldfinger N, Uysal A, Karabulut HG, Tukun A, Bokesoy L, Tuncman G, Rotter V. 1998. Molecular alteration in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia. Genes Chromosomes Cancer 21:2–7.
    Direct Link:
  • Petit B, Leroy K, Kanavaros P, Boulland M-L, Druet-Cabanac M, Haioun C, Bordessoule D, Gaulard P. 2001. Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations. Hum Pathol 32:196–204.
  • Pettitt AR, Sherrington PD, Cawley JC. 2000. Role of poly (ADP-ribosyl) ation in the killing of chronic lymphocytic leukemia cells by purine analogues. Cancer Res 60:4187–4193.
  • Pomerantz J, Schreiber-Agus N, Leigeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, Depinho RA. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713–723.
  • Preudhomme C, Fenaux P. 1997. The clinical significance of mutations of the p53 tumor suppressor gene in haematological. Br J Haematol 98:502–511.
    Direct Link:
  • Prokocimer M, Rotter V. 1994. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 84:2391–2411.
  • Prokocimer M, Peller S, Ben-Bassat H, Goldfinger N, Rotter V. 1998a. P53 gene mutation in a T-acute lymphoblastic leukemia cell line (loucy) with t (16:20) and 5q chromosomal aberrations. Leuk Lymphoma 29:607–611.
  • Prokocimer M, Unger R, Rennert HS, Rotter V, Rennert G. 1998b. Pooled analysis of p53 mutations in hematological malignancies. Hum Mutat 12:4–18.
    Direct Link:
  • Quintanilla-Martinez L, Kremer M, Keller G, Nathrath M, Gamboa-Dominguez A, Meneses A, Luna-Contreras L, Cabras A, Hoefler H, Mogar A, Fend F. 2001. P53 mutations in nasal natural killer/T-cell lymphoma from Mexico. Am J Pathol 159:2095–2105.
  • Sanchez-Aguilera A, Sanchez-Beato M, Garcia JF, Prieto I, Pollan M, Piris MA. 2002. P14ARF nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. Blood 99:1411–1418.
  • Shaw GR, Kronberger DI. 2000. TP53 deletions but not trisomy 12 are adverse in B-cell lymphoproliferative disorders. Cancer Genet Cytogenet 119:146–154.
  • Sigal A, Rotter V. 2000. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60:6788–6793.
  • Stilgenbauer S, Lichter P, Dohner H. 2000. Genetic features of B-cell chronic lymphocytic leukemia. Rev Clin Exp Hematol 4:48–72.
    Direct Link:
  • Stirewalt DL, Kenneth J, Meshinchi KS, Appelbaum FR, Slovak ML, Willman CL, Radich JP. 2001. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97:3589–3595.
  • Stokke T, Galteland E, Holte H, Smedshammer L, Suo Z, Smeland EB, Børresen-Dale AL, DeAngelis P, Steen HB. 2000. Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-Cell non-Hodgkin's lymphoma. Int J Cancer 89:313–324.
    Direct Link:
  • Takemoto S, Trovato R, Cereseto A, Nicot C, Kislyakova T, Casareto L, Waldmann T, Torelli G, Franchini G. 2000. P53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14ARF-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. Blood 95:3939–3944.
  • Wattel E, Preudhomme C, Hecquet B. 1994. P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148–3157.
  • Zhang Y, Xiong Y, Yarbrough WG. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725–734.
  • Zhou M, Gu L, Yeager AM, Findley HW. 1998. Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. Leukemia 12:1756–1763.
  • Zhou M, Gu L, Abshire TC, Homans A, Billett AL, Yeager AM, Findley HW. 2000. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 14:61–67.
  • Zhu X-H, Shen Y-L, Yong-Kui J, Xun C, Pei-Ming J, Ying H, Wei T, Gui-Ying S, Yue-Ping S, Jie D, Zhen-Yi W, Sai-Juan C, Ting-Dong Z, Samuel W, Zhu C, Guo-Qiang C. 1999a. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Nat Cancer Inst 91:772–778.
  • Zhu YM, Das-Gupta EP, Russell NH. 1999b. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood 94:733–740.
Get PDF (127K)